Molecular Signatures of Chronic Myeloid Leukemia Stem Cells

Overview

Journal Biomark Res

Publisher Biomed Central

Date 2013 Nov 21

PMID 24252550

Citations 6

Authors

Yaoyu Chen

Shaoguang Li

Affiliations

Soon will be listed here.

Abstract

BCR-ABL tyrosine kinase inhibitors (TKIs) are effective in controlling Philadelphia-positive (Ph+) chronic myeloid leukemia (CML) are unlikely to cure the disease because TKIs are unable to eradicate leukemia stem cells (LSCs) responsible for the disease relapse even after tyrosine kinase inhibition. In addition, the TKI resistance of LSCs is not associated with the BCR-ABL kinase domain mutations. These observations indicate that TKI-insensitive LSCs and TKI-sensitive leukemic progenitor cells are biologically different, which leads us to believe that LSCs and more differentiated leukemic cells have different genetic mechanisms. Further study of LSCs to identify the novel gene signatures and mechanisms that control the function and molecular phenotype of LSCs is critical. In this mini-review, we will discuss our current understanding of the biology of LSCs and novel genes that could serve as a molecular signature of LSCs in CML. These novel genes could also serve as potential targets for eradicating LSCs in CML.

Citing Articles

Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial.

Yen R, Grasedieck S, Wu A, Lin H, Su J, Rothe K Leukemia. 2022; 36(10):2443-2452.

PMID: 35999259 DOI: 10.1038/s41375-022-01680-4.

Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells.

Sheng Y, Ji Z, Zhao H, Wang J, Cheng C, Xu W Cell Prolif. 2019; 52(4):e12611.

PMID: 31054182 PMC: 6668982. DOI: 10.1111/cpr.12611.

Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.

Jin Y, Zhou J, Xu F, Jin B, Cui L, Wang Y J Clin Invest. 2016; 126(10):3961-3980.

PMID: 27643437 PMC: 5096815. DOI: 10.1172/JCI85239.

Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib.

Jin Y, Yao Y, Chen L, Zhu X, Jin B, Shen Y Theranostics. 2016; 6(11):1947-62.

PMID: 27570562 PMC: 4997248. DOI: 10.7150/thno.16139.

Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.

Aljedai A, Buckle A, Hiwarkar P, Syed F PLoS One. 2015; 10(4):e0123016.

PMID: 25849484 PMC: 4388554. DOI: 10.1371/journal.pone.0123016.

References

Chen Y, Sullivan C, Peng C, Shan Y, Hu Y, Li D . A tumor suppressor function of the Msr1 gene in leukemia stem cells of chronic myeloid leukemia. Blood. 2011; 118(2):390-400. PMC: 3138690. DOI: 10.1182/blood-2010-11-316760. View

Correa S, Binato R, Du Rocher B, Castelo-Branco M, Pizzatti L, Abdelhay E . Wnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia. BMC Cancer. 2012; 12:303. PMC: 3464798. DOI: 10.1186/1471-2407-12-303. View

Zhao C, Chen A, Jamieson C, Fereshteh M, Abrahamsson A, Blum J . Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature. 2009; 458(7239):776-9. PMC: 2946231. DOI: 10.1038/nature07737. View

Druker B, Sawyers C, Kantarjian H, Resta D, Reese S, Ford J . Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344(14):1038-42. DOI: 10.1056/NEJM200104053441402. View

Hui R, Gomes A, Constantinidou D, Costa J, Karadedou C, Fernandez de Mattos S . The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression. Mol Cell Biol. 2008; 28(19):5886-98. PMC: 2547013. DOI: 10.1128/MCB.01265-07. View

Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y . TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature. 2010; 463(7281):676-80. DOI: 10.1038/nature08734. View

Sullivan C, Chen Y, Shan Y, Hu Y, Peng C, Zhang H . Functional ramifications for the loss of P-selectin expression on hematopoietic and leukemic stem cells. PLoS One. 2011; 6(10):e26246. PMC: 3200313. DOI: 10.1371/journal.pone.0026246. View

Bhatia R, Holtz M, Niu N, Gray R, Snyder D, Sawyers C . Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003; 101(12):4701-7. DOI: 10.1182/blood-2002-09-2780. View

Peters-Golden M, Henderson Jr W . Leukotrienes. N Engl J Med. 2007; 357(18):1841-54. DOI: 10.1056/NEJMra071371. View

10.

Jordan C, Guzman M, Noble M . Cancer stem cells. N Engl J Med. 2006; 355(12):1253-61. DOI: 10.1056/NEJMra061808. View

11.

Druker B, Guilhot F, OBrien S, Gathmann I, Kantarjian H, Gattermann N . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355(23):2408-17. DOI: 10.1056/NEJMoa062867. View

12.

Dierks C, Beigi R, Guo G, Zirlik K, Stegert M, Manley P . Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell. 2008; 14(3):238-49. DOI: 10.1016/j.ccr.2008.08.003. View

13.

Krause D, Lazarides K, von Andrian U, Van Etten R . Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med. 2006; 12(10):1175-80. DOI: 10.1038/nm1489. View

14.

Rossi D, Jamieson C, Weissman I . Stems cells and the pathways to aging and cancer. Cell. 2008; 132(4):681-96. DOI: 10.1016/j.cell.2008.01.036. View

15.

Du J, Liu Y, Meline B, Kong G, Tan L, Lo J . Loss of CD44 attenuates aberrant GM-CSF signaling in Kras G12D hematopoietic progenitor/precursor cells and prolongs the survival of diseased animals. Leukemia. 2012; 27(3):754-7. PMC: 3602969. DOI: 10.1038/leu.2012.251. View

16.

Druker B, Sawyers C, Capdeville R, Ford J, Baccarani M, Goldman J . Chronic myelogenous leukemia. Hematology Am Soc Hematol Educ Program. 2001; :87-112. DOI: 10.1182/asheducation-2001.1.87. View

17.

Gao J, Graves S, Koch U, Liu S, Jankovic V, Buonamici S . Hedgehog signaling is dispensable for adult hematopoietic stem cell function. Cell Stem Cell. 2009; 4(6):548-58. PMC: 2914688. DOI: 10.1016/j.stem.2009.03.015. View

18.

Corbin A, Agarwal A, Loriaux M, Cortes J, Deininger M, Druker B . Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2010; 121(1):396-409. PMC: 3007128. DOI: 10.1172/JCI35721. View

19.

Zhang H, Li H, Xi H, Li S . HIF1α is required for survival maintenance of chronic myeloid leukemia stem cells. Blood. 2012; 119(11):2595-607. PMC: 3311277. DOI: 10.1182/blood-2011-10-387381. View

20.

Salomoni P, Pandolfi P . The role of PML in tumor suppression. Cell. 2002; 108(2):165-70. DOI: 10.1016/s0092-8674(02)00626-8. View